Crossing the Blood-Brain Barrier: Humanized Transport Mice for Brain-Targeted Drug Development
Free
- Length
- 1 hr
- Platform
- Zoom
- Topic
- More Webinars
About this webinar
Welcome to GemPharmatech's Webinar!
Less than 1% of a systemically dosed therapeutic antibody reaches the brain. Receptor-mediated transcytosis (RMT) is the leading non-invasive answer, and Roche’s Brainshuttle™ platform has taken it into Phase 3 with trontinemab — a roughly 50-fold improvement in CNS exposure over a conventional anti-amyloid antibody.
But there’s a catch for preclinical work. Shuttle modules are engineered against human TFRC, CD98HC and IGF1R. They don’t bind the mouse receptors. In a conventional rodent, the experiment simply can’t be run.
GemPharmatech’s humanized BBB transport mice replace the mouse receptor extracellular domain with its human counterpart, so human-targeted shuttles engage as designed. Each line is characterized for receptor expression and tolerability, and crosses with established AD, PD, HD and ALS models. We pair them with a microvessel-depletion brain PK workflow that distinguishes genuine parenchymal exposure from antibody trapped in the vasculature — the difference between a real delivery result and an artifact.
In this webinar:
1. The BBB and RMT delivery strategies, with Brainshuttle™ trontinemab as the clinical proof of concept
2. Our humanized RMT target models: receptor expression and safety data, and where humanization helps and where it doesn’t
3. The full BBB model library — TFRC, CD98HC and IGF1R on healthy backgrounds and crossed into AD, PD, HD and ALS
4. Brain PK assessment and efficacy evaluation in practice: anti-Aβ antibodies and AAV-mediated delivery